Peijun Tu
LightNews LightNews
rebecca2046.bsky.social
Peijun Tu
@rebecca2046.bsky.social
9 followers 24 following 9 posts
Senior Editor @ Nature Communications (cancer therapy). Views of my own.
Posts Replies Media Videos
rebecca2046.bsky.social
Check this News 👇 China seeks self-reliance in science in next five-year plan
www.nature.com/articles/d41...
#nature
China seeks self-reliance in science in next five-year plan
Beijing wants to double down on advanced semiconductor technologies, artificial intelligence and basic research.
www.nature.com
October 28, 2025 at 1:05 AM
rebecca2046.bsky.social
Phase 3 RCT published on NEJM: Sacituzumab tirumotecan monotherapy achieves better survival outcomes than platinum-based chemotherapy in patients with EGFR-mutated advanced or metastatic NSCLC progressed after previous EGFR-TKI therapy👇
www.nejm.org/doi/full/10....
#cancer #ClinicalTrial
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC | NEJM
Sacituzumab tirumotecan (sac-TMT) is an antibody–drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with EGFR-mutated non–small-cel...
www.nejm.org
October 22, 2025 at 1:00 AM
rebecca2046.bsky.social
Q&A: Translational Cancer Nanomedicine
We gather insights from two experts with distinct perspectives on cancer nanomedicine development 👇
www.nature.com/articles/s41...
September 18, 2025 at 5:42 AM
rebecca2046.bsky.social
28th Chinese Society of Clinical Oncology (CSCO) Annual Conference in Jinan, China, more information 👇
reg2025.csco.org.cn/35?lang=en
September 13, 2025 at 3:05 AM
rebecca2046.bsky.social
Check this recent publication in Nature Medicine👇： Phase 2 RCT indicates the potential of targeting dormant residual tumor cells with Chloroquine/Hydroxychloroquine, Everolimus or their combination in breast cancer survivors depletes minimal residual disease.
www.nature.com/articles/s41...
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial - Nature Medicine
A combination of mouse model data and data from a randomized phase 2 trial in patients with breast cancer in remission demonstrates feasibility, safety and a reduction in residual tumor cells followin...
www.nature.com
September 8, 2025 at 12:37 PM
Reposted by Peijun Tu
natrevcancer.nature.com
NEW content online!
3D chromatin architecture as a predictor of somatic mutations in cancer genomes
Nature Reviews Cancer, Published online: 01 September 2025; doi:10.1038/s41568-025-00875-yIn this Journal Club, Bansal and Mazumder discuss a study that investigated the interplay between three-dimensional genome structure and mutational load in cancer.
www.nature.com
September 1, 2025 at 2:31 PM
rebecca2046.bsky.social
The U.S. wants to phase out animal research. Are the alternatives ready? | Science | AAAS www.science.org/content/arti...
The U.S. wants to phase out animal research. Are the alternatives ready?
Drug and chemical safety can be assessed with AI and organ chips, but some scientists say it’s too soon to forgo animal methods entirely
www.science.org
August 26, 2025 at 10:41 AM
rebecca2046.bsky.social
Check this piece published on Nature (Aug 20th): Cancer-induced nerve injury promotes resistance3 to anti-PD-1 Therapy. This study highlights the importance of exploring cancer neuroscience to provide potential targets for resistance to cancer immunotherapy. 👇
www.nature.com/articles/s41...
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy - Nature
Perineural invasion and cancer-induced nerve injury of tumour-associated nerves are associated with poor response to anti-PD-1 therapy, which can be reversed by combining anti-PD-1 therapy with a...
www.nature.com
August 22, 2025 at 4:27 AM
rebecca2046.bsky.social
Editorial from Nature: Cancelling mRNA studies is the highest irresponsibility
www.nature.com/articles/d41...
Cancelling mRNA studies is the highest irresponsibility
The rest of the world is not following the US government’s dangerous path, and will stick with the technology that helped the world out of the COVID-19 pandemic.
www.nature.com
August 18, 2025 at 9:53 PM
rebecca2046.bsky.social
Older Women With High-risk Breast Cancer May Not Need Chemotherapy
theaacr.bsky.social American Association for Cancer Research (AACR) @theaacr.bsky.social · Aug 15
Some women over 70 may not need chemotherapy for high-risk breast cancer, pancreatic cancer vaccine trial links immune response and outcomes. Read these stories and more from Cancer Today magazine's Week in Cancer News. www.cancertodaymag.org/cancer-talk/...
August 15: The Week in Cancer News | Cancer Today
Women over 70 may not need chemotherapy for high-risk breast cancer, and a pancreatic cancer vaccine can trigger an immune response.
www.cancertodaymag.org
August 17, 2025 at 9:17 AM
Reposted by Peijun Tu
nature.com
Nature research paper: Respiratory viral infections awaken metastatic breast cancer cells in lungs

go.nature.com/4odw172
Respiratory viral infections awaken metastatic breast cancer cells in lungs - Nature
Mouse models show that respiratory infections from viruses such as influenza and SARS-CoV-2 can trigger metastasis of dormant breast cancer cells in the lungs, a finding supported by epidemiological data from two large human cohorts.
go.nature.com
August 4, 2025 at 8:02 AM
Reposted by Peijun Tu
nature.com
Two vaccine candidates using mRNA technology elicit a potent immune response against HIV

go.nature.com/4ov7WZI
mRNA vaccines for HIV trigger strong immune response in people
Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.
go.nature.com
August 1, 2025 at 8:40 AM